Dr. Trinh on the Recovery of Cancer Screening Tests Following First COVID-19 Pandemic Peak

Video

Quoc-Dien Trinh, MD, discusses findings from a study examining the temporal changes in cancer tests and diagnoses in a large healthcare system in the United States during the COVID-19 pandemic. 

Quoc-Dien Trinh, MD, associate professor of surgery, Harvard Medical School, and co-director, Dana-Farber/Brigham and Women's Prostate Cancer Center, discusses findings from a study examining the temporal changes in cancer tests and diagnoses in a large healthcare system in the United States during the COVID-19 pandemic. 

When examining the recovery of cancer screening tests following the first peak of the pandemic, it is not surprising that recovery did not occur equally across all disease states, as some tests are more complex than others, according to Trinh. For example, the logistics of a colonoscopy are more complicated than that of a prostate-specific antigen test, Trinh notes. For the latter, a patient can visit an affiliated center to receive a blood test; the former requires visiting the hospital to undergo an exam.

Documenting and quantifying the challenges faced to perform and recover these screening tests will help institutions understand the resources needed to address them, Trinh concludes.

Related Videos
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Debu Tripathy, MD
Changchun Deng, MD, PhD
Joaquim Bellmunt, MD, PhD
Timothy Yap, MBBS, PhD, FRCP
Parul N Barry, MD,
Ramez Kouzy, MD, MD Anderson
Bernard A. Fox, PhD
Bradley R. Corr, MD, associate professor, LeBert Suess Family Endowed Professor in Ovarian Cancer Research, gynecologic oncology team, the University of Colorado Anschutz Medical Campus